Tacrolimus-Induced Cardiomyopathy in a Kidney Transplant Recipient: A Reversible Cause of Left Ventricular Hypertrophy (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO1222; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Induction included antithymocyte globulin and steroids, followed by tacrolimus and mycophenolate mofetil...Tacrolimus was discontinued and replaced with belatacept...Improvement following tacrolimus withdrawal supports reversibility. Clinicians should consider tacrolimus toxicity in patients with new cardiomyopathy, as early recognition and modification of immunosuppression can improve outcomes."
Clinical • Amyloidosis • Antibody-mediated Rejection • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Chronic Kidney Disease • Diabetes • Fibrosis • Hypertension • Hypertrophic Cardiomyopathy • Immunology • Metabolic Disorders • Renal Disease • Transplantation
|
|
Abinay Siva kumar Reddy Vanteru; Krishna Vani Nemalidinne; Saad Abdulrahim Talal Mahmoud; Husam Mohammad Alzghoul; Nasir Khan
|